CONMED Corporation (NYSE:CNMD) Receives Consensus Recommendation of “Reduce” from Analysts

Shares of CONMED Corporation (NYSE:CNMD) have been assigned a consensus recommendation of “Reduce” from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $52.8333.

Several brokerages recently issued reports on CNMD. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CONMED in a research report on Wednesday, January 21st. JPMorgan Chase & Co. cut their price objective on shares of CONMED from $58.00 to $52.00 and set a “neutral” rating on the stock in a report on Thursday, November 6th. Wells Fargo & Company increased their price objective on shares of CONMED from $41.00 to $42.00 and gave the company an “equal weight” rating in a research report on Thursday. Zacks Research downgraded shares of CONMED from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 1st. Finally, Piper Sandler decreased their price target on shares of CONMED from $68.00 to $55.00 and set an “overweight” rating for the company in a report on Thursday, November 6th.

CONMED Trading Up 2.7%

NYSE:CNMD opened at $38.30 on Friday. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of 25.36, a PEG ratio of 1.66 and a beta of 0.96. CONMED has a 52 week low of $35.37 and a 52 week high of $74.70. The company has a quick ratio of 0.95, a current ratio of 2.10 and a debt-to-equity ratio of 0.85. The firm has a 50 day moving average of $41.33 and a 200 day moving average of $46.33.

CONMED (NYSE:CNMD) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $1.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.32 by $0.11. CONMED had a return on equity of 14.36% and a net margin of 3.42%.The business had revenue of $373.20 million for the quarter, compared to the consensus estimate of $366.88 million. During the same period in the prior year, the firm posted $1.34 earnings per share. The business’s quarterly revenue was up 7.9% on a year-over-year basis. As a group, sell-side analysts anticipate that CONMED will post 4.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Kelleher Financial Advisors acquired a new stake in shares of CONMED during the third quarter worth about $28,000. CWM LLC raised its position in CONMED by 352.0% during the 2nd quarter. CWM LLC now owns 791 shares of the company’s stock worth $41,000 after buying an additional 616 shares during the last quarter. Quarry LP lifted its stake in CONMED by 244.8% during the 3rd quarter. Quarry LP now owns 869 shares of the company’s stock valued at $41,000 after acquiring an additional 617 shares during the period. Huntington National Bank boosted its holdings in shares of CONMED by 111.8% in the 3rd quarter. Huntington National Bank now owns 883 shares of the company’s stock valued at $42,000 after acquiring an additional 466 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of CONMED in the second quarter worth $48,000.

Key Headlines Impacting CONMED

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q4 results beat analysts: CONMED reported $1.43 EPS (vs. $1.32 est.) and $373.2M revenue (vs. $366.9M est.), with revenue up ~7.9% year-over-year — this is the primary catalyst cited for the stock lift. Conmed: Q4 Earnings Snapshot
• Positive Sentiment: Gross-margin and surgical/orthopedic strength highlighted: coverage notes improved gross margin and outperformance in ortho/surgical segments drove the beat and underpin management’s 2026 outlook. CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up
• Positive Sentiment: Analyst note: Wells Fargo nudged its price target up to $42 (equal-weight), signaling modest upside from current levels and validating the quarter’s credibility. Benzinga
• Positive Sentiment: Management commentary and outlook: call highlights and deep-dive pieces emphasize strategic refocusing and ortho momentum setting the tone for 2026 expectations. CNMD Q4 Deep Dive: Ortho Outperformance and Strategic Refocusing Shape 2026 Outlook
• Neutral Sentiment: Earnings call transcripts and coverage are widely available for deeper read — useful for investors wanting management detail and segment-level commentary. Earnings Call Transcript
• Neutral Sentiment: Street posture mixed: Needham reaffirmed a Hold rating, indicating some analysts remain cautious despite the beat. Benzinga
• Neutral Sentiment: Analyst models: sell-side consensus still implies moderate 2026 earnings (consensus ~4.35 EPS), so follow-through depends on sustained ortho/surgical momentum and margin trends. Compared to Estimates, Conmed (CNMD) Q4 Earnings: A Look at Key Metrics
• Negative Sentiment: Technical/valuation headwinds remain: the stock still trades well below its 52‑week high and under longer-term moving averages, so multiple expansion may be limited absent sustained execution.

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.